Inhibikase Therapeutics, Inc. cotiza a 1.79 USD y tiene una capitalización bursátil de $250M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevate…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | — | $-0.09 | $-0.13 |
| Estimado | $-0.11 | $-0.09 | $-0.12 | $-0.13 |
| Sorpresa | — | — | +25.0% | +0.0% |
| Métrica | IKT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -27.9% | -40.4% | +12.5% |
| ROA | -26.6% | -32.0% | +5.4% |
| Current Ratio | 21.70 | 2.84 | +18.86 |
| Debt / Equity | — | 0.28 | — |